AstraZeneca is most likely to encounter a smaller sized penalty than formerly been afraid in China over thought overdue import tax obligation from cancer cells medicines, consisting of Imfinzi, Imjudo and perhaps additionally very successful Enhertu.
发布者:BY ULRICH QUISTGAARD,转转请注明出处:https://robotalks.cn/astrazeneca-optimistic-about-2025-following-reassuring-news-from-china/